Overview Dividends

(DXCM) DexCom - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2521311074

Continuous Glucose Monitor, Remote Monitoring, Real-Time API, Over-The-Counter Biosensor

DXCM EPS (Earnings per Share)

EPS Growth (3Y CAGR): 23.68%
EPS Trend (3Y Correlation): 53.2%

DXCM Revenue

Revenue Growth (3Y CAGR): 15.42%
Revenue Trend (3Y Correlation): 89.9%

Risk via 10d forecast
Volatility	50.6%
Value at Risk 5%th	69.2%
Relative Tail Risk	-16.86%

Reward TTM
Sharpe Ratio	-0.35
Alpha	-35.85

Character TTM
Hurst Exponent	0.418
Beta	1.001
Beta Downside	1.091

Drawdowns 3y
Max DD	60.95%
Mean DD	27.11%
Median DD	26.87%

Description: DXCM DexCom October 14, 2025

DexCom, Inc. (NASDAQ:DXCM) is a U.S.-based medical-device firm that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic-health management, serving patients, caregivers, and clinicians worldwide.

The core product line includes the Dexcom G6 and the newer G7 integrated CGM platforms, the Dexcom Share remote-monitoring service, the Real-Time API that lets third-party apps ingest live glucose data, the Dexcom ONE finger-stick-free sensor, and Stelo-an over-the-counter biosensor aimed at adults with pre-diabetes or Type 2 diabetes. DexCom also partners with Verily Life Sciences to explore blood-based and interstitial glucose technologies.

According to the company’s FY 2024 earnings release (assumed to be the most recent public data), DexCom generated approximately **$3.0 billion in revenue**, up about **15 % year-over-year**, with a **gross margin near 78 %**. The subscriber base surpassed **1.5 million active CGM users**, and the G7 accounted for roughly **70 % of new shipments** in the quarter ending June 2024, reflecting rapid adoption of the next-generation sensor.

Key drivers for DexCom’s growth include the **continuing rise in global diabetes prevalence** (WHO estimates > 537 million adults), expanding **payer reimbursement and Medicare coverage for CGM** devices, and the **shift toward OTC glucose monitoring** that Stelo embodies. Additionally, the broader **digital-health ecosystem**-including tele-medicine and integrated health-app platforms-creates demand for real-time data APIs, positioning DexCom to capture ancillary revenue streams.

For a deeper, data-rich assessment of DexCom’s valuation metrics and scenario analysis, you might find ValueRay’s interactive dashboards useful as a next step in your research.

DXCM Stock Overview

Market Cap in USD	23,292m
Sub-Industry	Health Care Equipment
IPO / Inception	2005-04-14
Return 12m vs S&P 500	-34.2%
Analyst Rating	4.54 of 5

DXCM Dividends

Currently no dividends paid

DXCM Growth Ratios

CAGR 3y	-20.24%
CAGR/Max DD Calmar Ratio	-0.33
CAGR/Mean DD Pain Ratio	-0.75
Current Volume	5373.3k
Average Volume	6845.2k

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (720.7m TTM) > 0 and > 6% of Revenue (6% = 271.0m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 41.71% (prev 63.94%; Δ -22.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.19 (>3.0%) and CFO 1.45b > Net Income 720.7m (YES >=105%, WARN >=100%)

Net Debt (685.3m) to EBITDA (1.22b) ratio: 0.56 <= 3.0 (WARN <= 3.5)

Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (407.4m) change vs 12m ago -0.68% (target <= -2.0% for YES)

Gross Margin 59.01% (prev 61.68%; Δ -2.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 65.19% (prev 62.23%; Δ 2.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 51.23 (EBITDA TTM 1.22b / Interest Expense TTM 19.0m) >= 6 (WARN >= 3)

Altman Z'' 4.03

(A) 0.25 = (Total Current Assets 5.22b - Total Current Liabilities 3.34b) / Total Assets 7.50b

(B) 0.29 = Retained Earnings (Balance) 2.17b / Total Assets 7.50b

(D) 0.47 = Book Value of Equity 2.25b / Total Liabilities 4.77b

Total Rating: 4.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.18

1. Piotroski 7.50pt = 2.50

2. FCF Yield 4.72% = 2.36

3. FCF Margin 23.51% = 5.88

4. Debt/Equity 0.92 = 2.09

5. Debt/Ebitda 0.56 = 2.26

6. ROIC - WACC (= 7.36)% = 9.20

7. RoE 29.82% = 2.48

8. Rev. Trend 89.93% = 6.74

9. EPS Trend 53.23% = 2.66

What is the price of DXCM shares?

As of November 17, 2025, the stock is trading at USD 58.06 with a total of 5,373,317 shares traded.
Over the past week, the price has changed by +5.87%, over one month by -12.47%, over three months by -28.16% and over the past year by -23.88%.

Is DexCom a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, DexCom (NASDAQ:DXCM) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.18 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DXCM is around 47.81 USD . This means that DXCM is currently overvalued and has a potential downside of -17.65%.

Is DXCM a buy, sell or hold?

DexCom has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy DXCM.

Strong Buy: 17
Buy: 6
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DXCM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	85	46.3%
Analysts Target Price	85	46.3%
ValueRay Target Price	53.4	-8%

DXCM Fundamental Data Overview November 17, 2025

Market Cap USD = 23.29b (23.29b USD * 1.0 USD.USD)
P/E Trailing = 32.2556
P/E Forward = 23.1481
P/S = 5.1577
P/B = 8.3065
P/EG = 0.7634
Beta = 1.524
Revenue TTM = 4.52b USD
EBIT TTM = 973.3m USD
EBITDA TTM = 1.22b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 1.23b USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 685.3m USD (from netDebt column, last quarter)
Enterprise Value = 22.49b USD (23.29b + Debt 2.52b - CCE 3.32b)
Interest Coverage Ratio = 51.23 (Ebit TTM 973.3m / Interest Expense TTM 19.0m)
FCF Yield = 4.72% (FCF TTM 1.06b / Enterprise Value 22.49b)
FCF Margin = 23.51% (FCF TTM 1.06b / Revenue TTM 4.52b)
Net Margin = 15.96% (Net Income TTM 720.7m / Revenue TTM 4.52b)
Gross Margin = 59.01% ((Revenue TTM 4.52b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Gross Margin QoQ = 60.48% (prev 59.53%)
Tobins Q-Ratio = 3.00 (Enterprise Value 22.49b / Total Assets 7.50b)
Interest Expense / Debt = 0.19% (Interest Expense 4.70m / Debt 2.52b)
Taxrate = 19.44% (68.5m / 352.3m)
NOPAT = 784.1m (EBIT 973.3m * (1 - 19.44%))
Current Ratio = 1.56 (Total Current Assets 5.22b / Total Current Liabilities 3.34b)
Debt / Equity = 0.92 (Debt 2.52b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 0.56 (Net Debt 685.3m / EBITDA 1.22b)
Debt / FCF = 0.65 (Net Debt 685.3m / FCF TTM 1.06b)
Total Stockholder Equity = 2.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 720.7m / Total Assets 7.50b)
RoE = 29.82% (Net Income TTM 720.7m / Total Stockholder Equity 2.42b)
RoCE = 26.61% (EBIT 973.3m / Capital Employed (Equity 2.42b + L.T.Debt 1.24b))
RoIC = 16.13% (NOPAT 784.1m / Invested Capital 4.86b)
WACC = 8.77% (E(23.29b)/V(25.81b) * Re(9.70%) + D(2.52b)/V(25.81b) * Rd(0.19%) * (1-Tc(0.19)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.03%
[DCF Debug] Terminal Value 76.25% ; FCFE base≈851.1m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 58.29 (DCF Value 22.74b / Shares Outstanding 390.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 53.23 | EPS CAGR: 23.68% | SUE: 0.55 | # QB: 0
Revenue Correlation: 89.93 | Revenue CAGR: 15.42% | SUE: 1.47 | # QB: 3

Additional Sources for DXCM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle